Literature DB >> 16679850

What's new in prostate cancer disease assessment in 2006?

Jonathan I Epstein1.   

Abstract

PURPOSE OF REVIEW: Issues relating to the disease are critical in the diagnosis, management, and prognostication of prostate cancer. RECENT
FINDINGS: New data have emerged regarding the disease of prostate cancer and its precursors. The diagnosis of prostate cancer on needle biopsy has been refined because of the recent discovery of alpha-methylacyl-CoA racemase, which preferentially labels adenocarcinoma of the prostate. Modifications and additions to the Gleason grading system were published based on a consensus conference of urological pathologists. Various models have been proposed using Gleason score, clinical findings, as well as measurements of tumor volume on needle biopsy to enhance the prediction in men undergoing radical prostatectomy and to predict "insignificance". Several studies have confirmed that certain findings in radical prostatectomy are adverse, yet conflicting studies were published as to the independent prognosis of tumor volume. The risk of cancer following a diagnosis of high-grade prostatic intraepithelial neoplasia on needle biopsy has decreased to the point at which this author does not recommend a routine repeat needle biopsy within the first year following the diagnosis of high-grade prostatic intraepithelial neoplasia.
SUMMARY: This review summarizes developments over the last year in the disease of prostate cancer and its precursors.

Entities:  

Mesh:

Year:  2006        PMID: 16679850     DOI: 10.1097/01.mou.0000193389.31727.9b

Source DB:  PubMed          Journal:  Curr Opin Urol        ISSN: 0963-0643            Impact factor:   2.309


  7 in total

1.  Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers.

Authors:  Ashish B Rajput; Melinda A Miller; Alessandro De Luca; Niki Boyd; Sam Leung; Antonio Hurtado-Coll; Ladan Fazli; Edward C Jones; Jodie B Palmer; Martin E Gleave; Michael E Cox; David G Huntsman
Journal:  J Clin Pathol       Date:  2007-01-26       Impact factor: 3.411

2.  Magnetic resonance imaging for prostate cancer clinical application.

Authors:  Bing Li; Yong Du; Hanfeng Yang; Yayong Huang; Jun Meng; Dongmei Xiao
Journal:  Chin J Cancer Res       Date:  2013-04       Impact factor: 5.087

3.  Molecular mapping of tumor heterogeneity on clinical tissue specimens with multiplexed quantum dots.

Authors:  Jian Liu; Stephen K Lau; Vijay A Varma; Richard A Moffitt; Matthew Caldwell; Tao Liu; Andrew N Young; John A Petros; Adeboye O Osunkoya; Tracey Krogstad; Brian Leyland-Jones; May D Wang; Shuming Nie
Journal:  ACS Nano       Date:  2010-05-25       Impact factor: 15.881

4.  Amide proton transfer (APT) magnetic resonance imaging of prostate cancer: comparison with Gleason scores.

Authors:  Yukihisa Takayama; Akihiro Nishie; Masaaki Sugimoto; Osamu Togao; Yoshiki Asayama; Kousei Ishigami; Yasuhiro Ushijima; Daisuke Okamoto; Nobuhiro Fujita; Akira Yokomizo; Jochen Keupp; Hiroshi Honda
Journal:  MAGMA       Date:  2016-03-10       Impact factor: 2.310

5.  Prediction of prostate cancer recurrence using magnetic resonance imaging and molecular profiles.

Authors:  Amita Shukla-Dave; Hedvig Hricak; Nicole Ishill; Chaya S Moskowitz; Marija Drobnjak; Victor E Reuter; Kristen L Zakian; Peter T Scardino; Carlos Cordon-Cardo
Journal:  Clin Cancer Res       Date:  2009-05-12       Impact factor: 12.531

6.  Correlation of MR imaging and MR spectroscopic imaging findings with Ki-67, phospho-Akt, and androgen receptor expression in prostate cancer.

Authors:  Amita Shukla-Dave; Hedvig Hricak; Nicole M Ishill; Chaya S Moskowitz; Marija Drobnjak; Victor E Reuter; Kristen L Zakian; Peter T Scardino; Carlos Cordon-Cardo
Journal:  Radiology       Date:  2009-03       Impact factor: 11.105

Review 7.  Dynamic contrast-enhanced magnetic resonance imaging of prostate cancer: A review of current methods and applications.

Authors:  Yousef Mazaheri; Oguz Akin; Hedvig Hricak
Journal:  World J Radiol       Date:  2017-12-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.